RT Journal Article
SR Electronic
T1 Striatal dopamine gene network moderates the effect of early adversity on the risk for adult psychiatric and cardiometabolic comorbidity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.23.22274209
DO 10.1101/2022.04.23.22274209
A1 Barth, Barbara
A1 Arcego, Danusa Mar
A1 de Mendonça Filho, Euclides José
A1 Merscher Sobreira de Lima, Randriely
A1 Parent, Carine
A1 Dalmaz, Carla
A1 Portella, André Krumel
A1 Pokhvisneva, Irina
A1 Meaney, Michael J
A1 Silveira, Patricia Pelufo
YR 2023
UL http://medrxiv.org/content/early/2023/12/15/2022.04.23.22274209.abstract
AB Cardiometabolic and psychiatric disorders often co-exist and share common early life risk factors, such as low birth weight. However, the biological pathways linking early adversity to adult cardiometabolic/psychiatric comorbidity remain unknown. Dopamine (DA) neurotransmission in the striatum is sensitive to early adversity and influences the development of both cardiometabolic and psychiatric diseases. Here we show that a co-expression based polygenic score (ePGS) reflecting individual variations in the expression of the striatal dopamine transporter gene (SLC6A3) network significantly interacts with birth weight to predict psychiatric and cardiometabolic comorbidities in both adults (UK Biobank, N= 225,972) and adolescents (ALSPAC, N= 1188). Decreased birth weight is associated with an increased risk for psychiatric and cardiometabolic comorbidities, but the effect is dependent on a striatal SLC6A3 ePGS, that reflects individual variation in gene expression of genes coexpressed with the SLC6A3 gene in the striatum. Neuroanatomical analyses revealed that SNPs from the striatum SLC6A3 ePGS were significantly associated with prefrontal cortex gray matter density, suggesting a neuroanatomical basis for the link between early adversity and psychiatric and cardiometabolic comorbidity. Our study reveals that psychiatric and cardiometabolic diseases share common developmental pathways and underlying neurobiological mechanisms that includes dopamine signaling in the prefrontal cortex.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research using ALSPAC was specifically funded by the Wellcome Trust and MRC (Grant ref: 076467/Z/05/Z) and Wellcome Trust (Grant ref: 08426812/Z/07/Z). This project was supported by The JPB Foundation through a grant to The JPB Research Network on Toxic Stress: A Project of the Center on the Developing Child at Harvard University. This work was also funded by the Fonds de recherche du Quebec Sante and Canadian Institutes of Health Research (CIHR, PJT 166066, PI Silveira PP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank: Informed consent was obtained from each participant, and the project has been approved by the North-West Multicentre Research 580 Ethics Committee (REC reference 11/NW/0382), the National Information Governance Board for Health and Social Care, and the Community Health Index Advisory Group for UK Biobank. Consenting participants provided baseline information, answered questions, had measurements and biological samples collected. This research has been conducted using the UK Biobank Resource under application number 41975. ALSPAC: Participants provided informed written consent to participate in the study. Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee and the local research ethics committees (a full list of the ethics committees that approved different aspects of the ALSPAC studies is available at http://www.bristol.ac.uk/alspac/researchers/research-ethics/). Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Consent for publication was obtained from UK Biobank and ALSPAC management teams. The use of these datasets was locally approved by the Centre integre universitaire de sante et de services sociaux de l'Ouest-de-l'Ile-de-Montreal Research Ethics Board under application number IUSMD-21-73. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor UK Biobank, data can be purchased; the study website contains details of all the data that is available at https://biobank.ndph.ox.ac.uk/showcase/. For ALSPAC, data can be purchased; the study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool at http://www.bristol.ac.uk/alspac/researchers/our-data/.